Target Price Range
Analyst price targets
Free account| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2023–2025 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | 414 | 466 | 379 | 302 | 156 | 125 |
Employees
|
|||
| — | — | — | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | 218 | 246 | 264 | 240 | 28 | 18 | 50 |
Revenue
|
|||
| — | — | — | 42.50% | 49.06% | 46.88% | 53.49% | 88.14% | 79.33% | 80.98% |
Gross Margin
|
|||
| — | — | — | (52) | (86) | (119) | (298) | (95) | (83) | (52) |
EBT
|
|||
| — | — | — | (23.83%) | (34.85%) | (45.00%) | (124.16%) | (341.46%) | (471.60%) | (104.00%) |
EBT Margin
|
|||
| — | — | — | (42) | (41) | (110) | (271) | (80) | (65) | (52) |
Net Income
|
|||
| — | — | — | 45 | 119 | 186 | 341 | 94 | 18 | 17 |
Depreciation
|
|||
| — | — | — | 218.46 | 5.73 | 5.82 | 4.58 | 0.46 | 0.26 | 0.55 |
Revenue/Sh
|
|||
| — | — | — | (41.82) | (0.96) | (2.42) | (5.17) | (1.31) | (0.96) | (0.58) |
Earnings/Sh
|
|||
| — | — | — | (44.79) | 1.35 | 0.83 | 0.64 | 0.29 | (0.81) | (0.42) |
Cash Flow/Sh
|
|||
| — | — | — | (15.93) | (0.16) | (0.09) | (0.08) | (0.05) | (0.03) | (0.01) |
Capex/Sh
|
|||
| — | — | — | (60.72) | 1.19 | 0.74 | 0.57 | 0.24 | (0.84) | (0.43) |
Free CF/Sh
|
|||
| — | — | — | 465.21 | 10.17 | 8.48 | 2.19 | 1.55 | 1.14 | 0.57 |
Book Value/Sh
|
|||
| — | — | — | 1 | 43 | 45 | 52 | 61 | 67 | 90 |
Shares
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | 1.39 | 1.39 | 1.33 | 1.53 | 3.41 | 4.99 | 2.08 |
PS Ratio
|
|||
| — | — | — | 0.84 | 0.84 | 0.91 | 3.19 | 2.75 | 1.14 | 2.02 |
PB Ratio
|
|||
| — | — | — | 2.52 | 2.52 | 2.08 | 2.25 | 4.82 | 5.32 | 2.33 |
EV/Sales
|
|||
| — | — | — | 24.13 | 24.13 | 16.42 | 18.24 | 25.26 | (1.65) | (3.00) |
EV/FCF
|
|||
| — | — | — | (45) | 58 | 38 | 34 | 18 | (55) | (38) |
Op' Cash Flow
|
|||
| — | — | — | (16) | (7) | (4) | (4) | (3) | (2) | (1) |
Capex
|
|||
| — | — | — | (61) | 51 | 33 | 30 | 14 | (57) | (39) |
FCF
|
|||
| — | — | — | (24) | (10) | 58 | 97 | 117 | 39 | 37 |
Working Cap'
|
|||
| — | — | — | 329 | 321 | 269 | 270 | 221 | 46 | 57 |
Total Debt
|
|||
| — | — | — | 309 | 286 | 198 | 174 | 107 | 6 | 12 |
Net Debt
|
|||
| — | — | — | 465 | 436 | 384 | 115 | 94 | 77 | 51 |
Sh' Equity
|
|||
| — | — | — | (4.41%) | (4.33%) | (12.79%) | (43.04%) | (19.08%) | (25.18%) | (37.84%) |
ROA
|
|||
| — | — | — | (2.59%) | (4.51%) | (10.59%) | (60.70%) | (28.25%) | (62.69%) | (58.06%) |
ROIC
|
|||
| — | — | — | (9.28%) | (9.13%) | (26.76%) | (108.67%) | (76.32%) | (76.11%) | (80.88%) |
ROE
|
|||
predictions in italic, sparklines do not include predictions
Fiscal years to Dec 2022 · latest quarter Jun 2023
RVL Pharmaceuticals PLC peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| NRSN NeuroSense Therapeutics Ltd. | $14.0M | 0.0× | Compare |
| CLVSQ Clovis Oncology, Inc. | $14.2M | 0.0× | Compare |
| CNSY Cerenome, Inc. | $14.3M | 0.0× | Compare |
| BIVI BioVie Inc. | $13.8M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| TPST Tempest Therapeutics, Inc. | $14.4M | 0.0× | Compare |
| HIND Vyome Holdings, Inc. | $14.5M | 0.0× | Compare |
| DARE Dare Bioscience, Inc. | $14.5M | 0.0× | Compare |
| ADAPY Adaptimmune Therapeutics PLC | $14.6M | 0.0× | Compare |
RVL Pharmaceuticals PLC (RVLP) key facts
- RVL Pharmaceuticals PLC (RVLP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- RVL Pharmaceuticals PLC’s revenue for fiscal 2022 (year ended December 2022) was $49.7 million.
- RVL Pharmaceuticals PLC reported a net loss of $51.7 million, or a loss of $0.58 per share, for fiscal 2022.
- Return on equity was −80.9% and debt-to-equity 3.54.
RVL Pharmaceuticals PLC (RVLP) Latest News
No news matches these filters.